新型冠狀病毒

Vaccine makers face revenue slump as demand falls for Covid-19 jabs
新冠疫苗製造商面臨收入下滑局面

Pharmaceutical companies hunt for new revenue streams as pandemic becomes endemic
隨著公衆對接種疫苗的冷漠程度加劇,新冠疫苗需求減弱,製藥公司開始尋找新的收入來源。

Makers of some of the most lucrative pharmaceutical products ever produced are headed for a slump in revenues as deliveries of Covid-19 vaccines almost halve next year, according to new forecasts.

根據最新預測,由於明年新冠疫苗的交付量幾乎減半,有史以來最賺錢的一些醫藥產品製造商將面臨收入下滑的局面。

您已閱讀5%(248字),剩餘95%(4565字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×